Tenax Therapeutics to Provide Corporate Update and Discuss Third Quarter Fiscal Year 2015 Financial Results on March 18, 2015

MORRISVILLE, N.C.--()--Tenax Therapeutics, Inc. (NASDAQ: TENX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced that the Company will host a conference call and live audio webcast on Wednesday, March 18, 2015, at 8:30 a.m. ET to provide a corporate update and discuss financial results for the third quarter fiscal year 2015 ended January 31, 2015.

To participate in the call, please dial 877‐407‐8029 (domestic) or 201‐689‐8029 (international) and refer to conference ID 13603008. A live webcast of the call can be accessed under “Events and Presentations” in the Investors section of the Company’s website at www.tenaxthera.com.

An archived webcast recording will be available on the Tenax Therapeutics website beginning approximately two hours after the call.

About Tenax Therapeutics

Tenax Therapeutics, Inc. (formerly Oxygen Biotherapeutics) is a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market. The company owns the North American rights to develop and commercialize levosimendan, and the United States Food and Drug Administration (FDA) has granted Fast Track status for levosimendan for the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome (LCOS). The company is currently enrolling a Phase 3 trial with levosimendan in that indication. For more information, visit www.tenaxthera.com.

Contacts

Investor Contact
Stern Investor Relations, Inc.
Jesse Baumgartner, 212-362-1200
jesse@sternir.com
or
Media Contact
Porter Novelli
Chad Hyett, 212-601-8242
chad.hyett@porternovelli.com

Release Summary

Tenax Therapeutics, Inc. (NASDAQ: TENX), to host conference call and live audio webcast March 18, 2015, at 8:30 a.m. ET to provide a corporate update and discuss 3rd quarter financial results.

Contacts

Investor Contact
Stern Investor Relations, Inc.
Jesse Baumgartner, 212-362-1200
jesse@sternir.com
or
Media Contact
Porter Novelli
Chad Hyett, 212-601-8242
chad.hyett@porternovelli.com